AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin prick-test
Description: Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin prick-test
Description: Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA.
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample collection
Description: A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA.
Study NCT01227720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT) 2 mg
Description: 2 mg Single-dose of new NRT product (NSL2L)
Study NCT01227720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Nicotine Replacement Therapy (NRT)
Description: 4 mg Single-dose of new NRT product
Study NCT01227720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Lozenge
Description: 2 mg Single-dose of marketed lozenge
Study NCT01227720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Lozenge
Description: 4 mg Single-dose of marketed lozenge
Study NCT01268904 — intervention group
Intervention type: DRUG
Intervention: Valproate
Description: Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
Study NCT02853149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Cord Injury (SCI)
Description: The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program.
Study NCT02853149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Intervention(CCC)
Description: The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program.
Study NCT02853149 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver Control (CC)
Description: The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
Study NCT02089503 — intervention group
Intervention type: OTHER
Intervention: intravitreal injections of Lucentis
Description: intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
Study NCT06792409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive breast augmentation procedure with a trans-axillary approach.
Description: Minimally invasive breast augmentation procedure with a transaxillary approach using Motiva Ergonomix2 Diamond®, Motiva Injector® and Motiva® Inflatable Balloon.
Study NCT01817660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair of popliteal artery
Study NCT01817660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular repair of popliteal artery
Study NCT03599271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device
Description: Sinus dilation device without drug
Study NCT00882063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
Study NCT03568695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Two samples on each of the three sites (pharynx, rectum, urine)
Description: two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
Study NCT01090674 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
Study NCT01779804 — intervention group
Intervention type: PROCEDURE
Intervention: OFAR
Description: OFAR
Study NCT03312101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
Study NCT05651984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between communication board and eye tracking
Description: The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
Study NCT05651984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between communication board and eye tracking
Description: The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
Study NCT05136040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
Study NCT02635529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+ DFDBA
Description: After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
Study NCT02635529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+ DFDBA+ AM
Description: After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
Study NCT01690819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ventilatory Strategy
Description: The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
Study NCT01690819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective Ventilatory Strategy
Description: The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
Study NCT04039763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Realtime Continous Glucose Monitoring
Study NCT04039763 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Self monitoring of blood glucose
Description: Finger prick self monitoring of blood glucose
Study NCT02901080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim AID cranial electrotherapy stimulation
Description: - 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
Study NCT02901080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: - Pregnancy test x 1 (day 1)
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety questionnaire
Description: - GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study NCT00820846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA vaccine
Description: 1 mL of pGA2/JS7 DNA vaccine
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: - EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Work and social questionnaire
Description: - WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep questionnaire
Description: - Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression questionnaire
Description: - PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study NCT02901080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life and financial questionnaire
Description: - CSRI questionnaire x 3 (day 1, week 12 and week 24)
Study NCT05527106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
Study NCT05527106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
Study NCT05527106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline and Docosahexaenoic Acid (DHA)
Description: Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
Study NCT05527106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
Study NCT03766542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure with ventilatory support
Description: Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
Study NCT03766542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure without ventilatory support
Description: Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
Study NCT04125992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial artery access in coronary angiography and angioplasty
Description: The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis.
Study NCT04125992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm radial artery access in coronary angiography and angioplasty
Description: The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis.
Study NCT00006083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin
Description: Fragmin at 5000 IU injected subcutaneously daily
Study NCT00006083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injected subcutaneously daily
Study NCT00593736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
Study NCT00593736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
Study NCT00593736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
Study NCT00820846 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of sodium chloride for injection
Study NCT00820846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mL of sodium chloride for injection
Study NCT00820846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62 vaccine
Description: 1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
Study NCT02533856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETOC
Description: Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
Study NCT03746457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy
Study NCT03746457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy
Study NCT06792331 — intervention group
Intervention type: PROCEDURE
Intervention: vNOTES high uterosacral ligament suspension
Description: Following the entry into the peritoneal cavity via apical colpotomy, a transvaginal retractor was inserted through the vaginal vault and the vaginal access platform was established. The ureters and uterosacral ligaments (USL) were identified via laparoscopic view. Bilateral nonabsorbable sutures were placed by the intermediate portions of the USL at the level of the ischial spines making up a total of 4 stitches (Figure 1). Then, the sutures were slightly weighed to verify proper placement. Then, the V-notes platform was removed and the peritoneum was closed. The aforementioned sutures were fixed to the ipsilateral cardinal ligament stump and the pubocervical fascia on the anterior wall. Finally, the previously mentioned nonabsorbable sutures were attached to the vaginal cuff and tied. Routine postoperative cystoscopy was performed.
Study NCT06792331 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic lateral suspension
Description: The polypropylene mesh used had a width of 2.5 cm and a length of 25 cm. The vaginal cuff was suspended. Blunt dissection was applied to develop vesicovaginal and rectovaginal spaces. The middle part of the mesh was placed flatly in the vesicovaginal space, and fixed with non-absorbable sutures. An atraumatic laparoscopic instrument was inserted through skin incisions of approximately 2-3 mm approximately 3 cm above and 4 cm lateral to the anterior superior iliac spine, followed by perforation only of the aponeurosis of the external oblique muscle and retroperitoneal advancement of the instrument through the lateral abdominal wall. Under laparoscopic visualization, the instrument moved through the bilateral tension-free retroperitoneal tunnels created. The lateral arms of the mesh were secured bilaterally to the aponeurosis of the external oblique muscle and behind the anterior superior iliac spine. Finally, the peritoneum was closed.
Study NCT00593736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
Study NCT03049605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic therapy
Description: low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
Study NCT03049605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
Study NCT00823095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
Study NCT02265874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Habitrol
Description: Patch used daily for 28 weeks
Study NCT02265874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Habitrol
Study NCT02871414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST - Early Group
Description: Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
Study NCT02251171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02251171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02251171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin